Patents Issued in March 4, 2014
  • Patent number: 8664341
    Abstract: Embodiments include vinylbenzyl ethers of polycyclopentadiene polyphenol that can be obtained by reacting a polycyclopentadiene polyphenol with a vinylbenzyl halide. Embodiments also include thermosettable compositions including the vinylbenzyl ethers of a polycyclopentadiene polyphenol and products obtained by curing the thermosettable compositions. Formula (I).
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: March 4, 2014
    Assignee: Dow Global Technologies, LLC
    Inventor: Robert E. Hefner, Jr.
  • Patent number: 8664342
    Abstract: Process for introducing a solid polymerization catalyst into a gas-phase fluidized bed using an injection device having an inner tube of internal cross-sectional area of 10 to 100 mm2 and an outer tube forming an annulus around the inner tube with a cross-sectional area of 1 to 10 times the internal cross-sectional area of the inner tube. The polymerization catalyst and a carrier gas are passed through the inner tube and into the gas-phase fluidized bed at a carrier gas linear velocity of 4 to 14 m/s and a carrier gas mass flow rate of 10-35 kg/h. A shielding gas is passed through the outer tube and into the gas-phase fluidized bed at a linear velocity of 1 to 10 times the carrier gas linear velocity through the inner tube and at a mass flow rate of 100-500 kg/h. No cooled recycle process gas is provided to the injection device.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: March 4, 2014
    Assignee: Ineos Commercial Services UK Limited
    Inventors: Bruno Bordais, Christohper James Kemp, Jose Andre Laille, Willy Lemesle
  • Patent number: 8664343
    Abstract: A polymerization catalyst composition for preparing cis 1,4-polydienes is provided. The catalyst composition comprises (a) a metal-containing compound, said metal being a transition metal or a lanthanide metal; (b) a carbene, (c) an alkylating agent, and optionally (d) a halogen-containing compound with the proviso that the halogen-containing compound must be present when none of the metal-containing compound and the alkylating agent contain a labile halogen atom. Also provided is a process for producing a polydiene comprising reacting a conjugated diene in the presence of the polymerization catalyst composition.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: March 4, 2014
    Assignee: Bridgestone Corporation
    Inventors: Zengquan Qin, Jason T. Poulton
  • Patent number: 8664344
    Abstract: Process for the preparation of polybutadiene effected by the polymerization of butadiene in an aliphatic and/or cyclo-aliphatic solvent in the presence of a catalytic system prepared in situ which comprises: (i) a carboxylate of neodymium soluble in the process solvent containing a variable quantity of water, the H2O/Nd molar ratio ranging from 0.001/1 to 0.50/1; (ii) an alkyl compound of aluminum; (iii) an alkyl compound of aluminum in which at least one bond of Al consists of an Al—Cl bond; The total Al/Nd molar ratio ranging from 4/1 to 12/1, and the Cl/Nd molar ratio ranging from 2/1 to 6/1.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: March 4, 2014
    Assignee: Polimeri Europa S.p.A.
    Inventors: Gian Tommaso Viola, Marianna Zinna
  • Patent number: 8664345
    Abstract: This invention describes a process for the preparation of a catalytic composition that can be used for oligomerization, codimerization, or polymerization of olefins. This invention also describes the catalytic composition that can be obtained by said process for the preparation and its use for oligomerization, codimerization, or polymerization of olefins.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: March 4, 2014
    Assignee: IFP Energies nouvelles
    Inventors: Claudine Rangheard, Helene Olivier-Bourbigou, David Proriol
  • Patent number: 8664346
    Abstract: A targeted molecular weight of an organopolysiloxane is obtained in a two stage hydrolysis by hydrolyzing a chlorosilane with from 0.002 to 0.6 mol of water in a first step in the presence of alcohol, in which the pressure and/or temperature are adjusted such that following further hydrolysis in a second step, the targeted molecular weight is obtained.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: March 4, 2014
    Assignee: Wacker Chemie AG
    Inventor: Gerhard Staiger
  • Patent number: 8664347
    Abstract: Silicone-polyether block copolymers are disclosed, having the average formula: R4R12Si(OR52Si)m{[R2O(CqH2qO)pR2R12Si(OR52Si)k]nR2O(CqH2qO)pR2R12Si)m}hOSiR12R4 wherein R1 is C1-C10 hydrocarbyl; R2 is C1-C10 hydrocarbylene; R3 is R1 or H; R4 is —R2—NR32 or —R2—NR3—R2—NR32; R5 is R1 or R4; h is 1 to 100; k is 2 to 500; m is 2 to 500; n is 0 to 30; p is 2 to 120; and q is 2 to 4. The silicone-polyether block copolymers comprise two terminal amine functionalities and may comprise varying degrees of pendent amine functionality. In a method for synthesizing linear silicone-polyether block copolymers of the above formula, a reaction mixture is formed by combining a polyether, an organosilicon component, an endblocking agent, and a catalyst. Thereupon, the reaction mixture is heated to produce a silicone-polyether block copolymer having at least one pendent amine functionality and a number-average molecular weight from 2000 to 500,000.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: March 4, 2014
    Assignee: Dow Corning Corporation
    Inventors: Brian P. Deeth, John Joseph Kennan, Kevin Dale Lewis
  • Patent number: 8664348
    Abstract: New triaminophenol compositions and related compounds are disclosed, as are processes for their preparation and for the preparation of novel salts and diacid complexes from such compounds. Polymers prepared from these compositions can be made into high strength fiber, film, and tape and are useful in applications such as protective apparel, aircraft, automotive components, personal electronics, and sports equipment.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: March 4, 2014
    Assignee: E I du Pont de Nemours and Company
    Inventors: Rajiv Dhawan, Joachim C Ritter, Frederick K Mallon, Steven R Allen, David J Rodini, Roger K Siemionko
  • Patent number: 8664349
    Abstract: The present invention relates to polycarbonate compositions and copolycarbonate compositions having improved optical properties, and to their production and their use for the production of shaped parts, and to shaped parts which can thereby be obtained, the compositions containing a polycarbonate or copolycarbonate which comprises bisphenol-A and at least one pair of a phosphorus compound having the oxidation number +3 and a phosphorus compound having the oxidation number +5, and the phosphorus compound having the oxidation state +5 in a pair respectively corresponding to the oxidized form of the phosphorus compound having the oxidation state +3 and the amount of more highly oxidized compound contained being less than that of the compound with the lower oxidation number.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: March 4, 2014
    Assignee: Bayer MaterialScience AG
    Inventors: Rolf Wehrmann, Helmut-Werner Heuer, Anke Boumans
  • Patent number: 8664350
    Abstract: The invention relates to a composition containing a particulate solid, a plastic material and a compound. The invention further relates to novel compounds, and the use of the coupling agents.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: March 4, 2014
    Assignee: Lubrizol Limited
    Inventor: Dean Thetford
  • Patent number: 8664351
    Abstract: The present invention provides a biaxially oriented polyester film for a backsheet of solar batteries which exhibits a good hydrolysis resistance and a low haze. The present invention relates to a biaxially oriented polyester film for a backsheet of solar batteries, comprising titanium in an amount of not more than 20 ppm in terms of a titanium atom, phosphorus in an amount of not more than 70 ppm in terms of a phosphorus atom, and antimony in an amount of not more than 10 ppm in terms of an antimony atom; and having a carboxyl end group content of not more than 26 equivalents/t and an intrinsic viscosity of 0.65 to 0.90.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: March 4, 2014
    Assignee: Mitsubishi Plastics, Inc.
    Inventors: Koutarou Nozawa, Taku Aoike
  • Patent number: 8664352
    Abstract: A polyester polyol made from natural oil feedstocks is disclosed. Methods for making the polyol are also disclosed. The method comprises reacting hydroxylated fatty acid/alkyl esters with a multifunctional ester-reactive initiator compound to form the polyester polyol. In one embodiment, the hydroxylated fatty acid/alkyl esters are made by hydroxylating fatty acid/alkyl esters having up to ninety-five percent by weight monounsaturation.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: March 4, 2014
    Assignee: Cargill, Incorporated
    Inventors: Timothy Walter Abraham, Jeff J. Malsam
  • Patent number: 8664353
    Abstract: A process for purifying a polyol(per)fluoropolyether derivative [polyol (P)] from a mixture (M) of hydroxyl(per)fluoropolyether derivatives, such polyol (P) comprising one or more hydroxyl(per)fluoropolyether derivatives [PFPEs (OH)] comprising at least one (per)fluoropolyoxyalkylene chain (chain Rf) and at least one end-group having formula (t3): —CF2CH2OCH2CH(OH)CH2OCH2CH(OH)CH2OH, such mixture (M) comprising said polyol (P) and at least one hydroxyl(per)fluoropolyether derivative [PFPE (OH)] different from polyol (P) and comprising at least one chain Rf and at least one end-group selected from end-groups having formula (t1): —CF2CH2OH and formula (t2): —CF2CH2OCH2CH(OH)CH2OH.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: March 4, 2014
    Assignee: Solvay Solexis S.P.A.
    Inventors: Claudio Adolfo Pietro Tonelli, Graziano Giuseppe Vezzulli, Rosaldo Picozzi, Piero Gavezotti
  • Patent number: 8664354
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: March 4, 2014
    Assignee: Synergy Pharmaceuticals Inc.
    Inventor: Kunwar Shailubhai
  • Patent number: 8664355
    Abstract: It is provided a simple and efficient process for producing a large amount of protein in a cell-free protein synthesis system, through a continuous synthesis reaction over a long time using a linear DNA as a template. The continuous synthesis reaction is carried out for at least one hour with a cell-free protein synthesis system comprising an extract of Escherichia coli cells cultured at any temperature between 18° C. and 36° C., and a linear template DNA encoding the protein. The continuous protein synthesis system is preferably a dialysis system or a continuous flow system. The cell-free protein synthesis system by dialysis system comprises an internal dialysate comprising the extract and the linear template DNA, an external dialysate comprising a substrate solution for protein synthesis, and a dialysis membrane through which the substrate can be transferred.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: March 4, 2014
    Assignee: Riken
    Inventors: Natsuko Matsuda, Takanori Kigawa, Shigeyuki Yokoyama
  • Patent number: 8664356
    Abstract: The invention provides compounds and methods, for example, to carry out organocatalytic Michael additions of aldehydes to cyclically constrained nitroethylene compounds catalyzed by a proline derivative to provide cyclically constrained ?-substituted-?-nitro-aldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96 to >99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to cyclically constrained protected ?-amino acid residues, which are essential for systematic conformational studies of ?-peptide foldamers. New methods are also provided to prepare other ?-amino acids and peptides. These new building blocks can be used to prepare foldamers, such as ?/?-peptide foldamers, that adopt specific helical conformations in solution and in the solid state.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: March 4, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Samuel Helmer Gellman, Li Guo, Michael Giuliano
  • Patent number: 8664357
    Abstract: According to the present invention, there is provided a process for the preparation of a first compound selected from peptides, oligonucleotides and peptide nucleic acids. The process comprises synthesizing the first compound and then separating the first compound formed in step (i) from a second compound, which is a reaction by-product of the synthesis of the first compound and/or an excess of a reagent used for the synthesis of a first compound by a process of diafiltration. The membrane used for the diafiltration process is stable in organic solvents and provides a rejection for the first compound which is greater than the rejection for the second compound.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: March 4, 2014
    Assignee: Imperial Innovations Limited
    Inventors: Andrew Guy Livingston, Ludmila Georgieva Peeva, Sheyung Wang Jerry So, Renato Campos Vasconceles, Robin John Leatherbarrow, Edward William Tate, Piers Robert James Gaffney
  • Patent number: 8664358
    Abstract: Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: March 4, 2014
    Assignee: Vermillion, Inc.
    Inventors: Brian C. Mansfield, Ping F. Yip, Suraj Amonkar, Greg P. Bertenshaw
  • Patent number: 8664359
    Abstract: The invention is related to isoforms of components of transcription factor complexes that are specifically expressed in cancer cells. These isoforms can be used as biomarkers for detection, diagnosis, prognosis and monitoring of treatments of cancer, and as drug targets of pharmaceutical compositions for the treatment of various cancers expressing the targeted isoforms. Methods, molecules, materials and kits for these uses are disclosed.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: March 4, 2014
    Assignee: OncoTx, Inc.
    Inventors: Anna Kazantseva, Jekaterina Kazantseva
  • Patent number: 8664360
    Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: March 4, 2014
    Assignee: Bristols-Myers Squibb Company
    Inventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
  • Patent number: 8664361
    Abstract: Soy products or compositions are treated with a food grade iodate compound or a cystine compound to reduce levels of methanethiol, sulfites and sulfite free-radicals, sulfate free radicals and other free radicals generated from sulfite free radicals in the soy products or compositions by 1% to 95%.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: March 4, 2014
    Assignee: University of Kentucky Research Foundation
    Inventor: William L. Boatright
  • Patent number: 8664362
    Abstract: An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3CDRs in SEQ ID NO: 1 and light chain variable domain including the 3 CDRS in SEQ ID NO: 9.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: March 4, 2014
    Assignee: Novelmed Therapeutics
    Inventor: Rekha Bansal
  • Patent number: 8664363
    Abstract: Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and light chain variable region (“VK”). The FW regions may contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. The human or humanized VH framework regions may comprise one or more of the following residues: a valine at position 24 of FW1, a glycine at position 49 of FW2, and an asparagine at position 73 of FW3, numbered according to Kabat. Further provided are pharmaceutical and immunotherapeutic compositions, and methods using anti-CD22 antibodies that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases in humans, including B cell malignancies, autoimmune disease, GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: March 4, 2014
    Assignee: MedImmune, LLC
    Inventors: Tarran Jones, David G. Williams
  • Patent number: 8664364
    Abstract: Provided are biosensors, compositions comprising biosensors, and methods of using biosensors in living cells and organisms. The biosensors are able to be selectively targeted to certain regions or structures within a cell. The biosensors may provide a signal when the biosensor is targeted and/or in response to a property of the cell or organism such as membrane potential, ion concentration or enzyme activity.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: March 4, 2014
    Assignee: Carnegie Mellon University
    Inventors: Brigitte F. Schmidt, Christopher S. Szent-Gyorgyi, Alan S. Waggoner, Peter B. Berget, Marcel P. Bruchez, Jonathan W. Jarvik
  • Patent number: 8664365
    Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: March 4, 2014
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
  • Patent number: 8664366
    Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: March 4, 2014
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
  • Patent number: 8664367
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: March 20, 2013
    Date of Patent: March 4, 2014
    Assignee: AbbVie, Inc.
    Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
  • Patent number: 8664368
    Abstract: The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: March 4, 2014
    Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.
    Inventors: Shuhui Wang, Chuan Li, Ying Kan, Xin Tong
  • Patent number: 8664369
    Abstract: The invention relates to liquid pharmaceutical formulations of luteinizing hormone (LH) for single- or multi-dose administration.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: March 4, 2014
    Assignee: Merck Serono S.A.
    Inventors: Rita Agostinetto, Fabrizio Samaritani, Alessandra Del Rio, Joel Richard
  • Patent number: 8664370
    Abstract: The invention relates to a process for preparing silicon-containing azodicarbamides of the general formula (I) (R1)3-a(R2)aSi—RI—NH—C(O)—N?N—C(O)—NH—RI—Si(R1)3-a(R2)a (I), by reaction of azobiscarboxy compounds of the general formula II R3—X1—C(O)—N?N—C(O)—X1—R4 (II) with aminosilanes of the general formula III (R1)3-a(R2)aSi—RI—NH2 (III).
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: March 4, 2014
    Assignee: Evonik Degussa GmbH
    Inventors: Karsten Korth, Julia Keck, Susann Witzsche, Oliver Klockmann, Jaroslaw Monkiewicz, Christian Springer
  • Patent number: 8664371
    Abstract: Rinsable dyes with improved fugitivity are formulated by attaching dyestuff compounds with amine-capped sulfonic solubilizing groups to commercially available ethoxylated aniline, so that the surfactant effect of the ethoxylated aniline counteracts the substantivity of the dyestuff compound, while the neutralization of the sulfonic solubilizing groups reduces substantivity.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: March 4, 2014
    Assignee: Spectra Colors Corp.
    Inventors: Mark Berenfeld, Sal Harfouch, Peter Caputo
  • Patent number: 8664372
    Abstract: In preparing a glycoside compound from (a) a furanose compound or pyranose compound, and (b) an alcohol compound, a process for preparing a glycoside compound in which glycosidic bond locates selectively trans form relative to C-2 hydroxyl group, the process comprising using a furanose compound wherein the hydroxyl at the 2-position may have a substituent protected with a group A, or a pyranose compound which may have a substituent wherein R2 and R3 are the same or different and are each alkyl having 1 to 4 carbon atoms or aryl having or not having a substituent, or R2 and R3 are combined to form alkylene having 2 to 4 carbon atoms (the alkylene may be substituted with alkyl having 1 to 4 carbon atoms, or may have intervening phenylene), and m and n are each an integer of 0 or 1.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: March 4, 2014
    Assignee: Glytech, Inc.
    Inventor: Shigeru Yamago
  • Patent number: 8664373
    Abstract: The present invention provides a low-cost, efficient method for producing a glycolipid biosurfactant, in particular, lactonic sophorose lipids. This method is characterized by culturing a microorganism capable of producing the biosurfactant under limited oxygen supply. The present invention enables preferential production of lactonic sophorose lipids and facilitates recovery of the lactonic sophorose lipids in a solid form. Further, the present invention enables production of high purity acidic sophorose lipids by hydrolyzing high purity lactonic sophorose lipids produced by the above method. The present invention also provides lactonic sophorose lipids that possess strong antibacterial and antifungal activities, and an antibacterial and/or antifungal agent containing the sophorose lipids.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: March 4, 2014
    Assignee: Kaneka Corporation
    Inventors: Satohiro Yanagisawa, Shigeru Kawano, Yoshihiko Yasohara
  • Patent number: 8664374
    Abstract: This invention is directed to methods for recombinant polypeptide production and, in particular, methods and products for the production of recombinant polypeptides in ciliates.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: March 4, 2014
    Assignee: Tetragenetics, Inc.
    Inventors: Paul Colussi, Donna Cassidy-Hanley, Theodore G. Clark
  • Patent number: 8664375
    Abstract: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: March 4, 2014
    Assignee: Alcon Research, Ltd.
    Inventor: Jon E. Chatterton
  • Patent number: 8664376
    Abstract: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1—2 (SEQ ID NOS: 60 and 127), SERPINH1—45a (SEQ ID NOS: 98 and 165), and SERPINH1—51 (SEQ ID NOS: 101 and 168), and drug carrier comprising a mixture of a retinoid and a lipid vesicle, and methods of using these pharmaceutical compositions to treat a disease associated with hsp47 espresssion, including fibrosis.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: March 4, 2014
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu
  • Patent number: 8664377
    Abstract: A method and apparatus for efficiently isolating nucleic acids from a nucleic acid-containing sample.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: March 4, 2014
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Kyu-youn Hwang, Joon-ho Kim, Kak Namkoong
  • Patent number: 8664378
    Abstract: The present invention solves the problem of isolating nucleic acids from cells in the presence of the growth medium. The invention is particularly useful for isolating extrachromosomal replicons such as plasmids. Cells are lysed in the presence of the medium in which they were grown and nucleic acids are isolated using a pipette tip column. A liquid handling robot can be used to isolate nucleic acids from multiple samples simultaneously without the need for human intervention.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: March 4, 2014
    Assignee: PhyNexus, Inc.
    Inventors: Chris Suh, Lee Hoang, Douglas T. Gjerde
  • Patent number: 8664379
    Abstract: The present invention relates to sodium channel inhibitors of Formula I: in which R1, R2, R3, R4, R5, R6, and R7 are as defined above, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: March 4, 2014
    Assignee: Gilead Sciences, INc.
    Inventors: Matthew Abelman, Nancy Chu, Robert H. Jiang, Kwan Leung, Jeff Zablocki
  • Patent number: 8664380
    Abstract: Compounds represented by the formulas wherein each symbol is as defined in the specification, and a prodrug thereof have a superior renin inhibitory activity, and are useful as agents for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: March 4, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takanobu Kuroita, Yasuhiro Imaeda, Kouichi Iwanaga, Naohiro Taya, Hidekazu Tokuhara
  • Patent number: 8664381
    Abstract: The present invention relates to a process for the purification of amorolfine hydrochloride by means of a reversed-phase preparative high performances liquid chromatography (prep-HPLC) said method starting from a crude Amorolfine hydrochloride having purity higher than 90% and containing Bepromoline hydrochloride <5% and Fenpropimorf <3%. The process involves the use of a mobile phase comprising water and an organic solvent under isocratic conditions.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: March 4, 2014
    Assignee: SYNTECO S.p.A.
    Inventors: Roberto Angeli, Marco Possenti, Salvatore Demartis
  • Patent number: 8664382
    Abstract: The present invention relates to pharmaceutical compositions comprising metal phthalocyanine analogues of formula (I) and metal chelating compounds having a good bioavailability and enhanced photoinactivation properties against Gram negative bacteria; and to their use for in vivolex vivo applications, such as blood and blood derivatives sterilization.
    Type: Grant
    Filed: April 17, 2003
    Date of Patent: March 4, 2014
    Assignee: Molteni Therapeutics S.r.l.
    Inventors: Gabrio Roncucci, Donata Dei, Giacomo Chiti, Lia Fantetti, Francesco Giuliani, Giulio Jori, Gian Maria Rossolini
  • Patent number: 8664383
    Abstract: Disclosed is an organometallic complex capable of variable phosphorescence characteristics and yellow emission at high luminance The organometallic complex has a structure represented by a formula (G6), where at least one of R4, R5, R6, and R7 is a phenoxy group, M is a Group 9 metal or a Group 10 metal, and L is a monoanionic ligand.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: March 4, 2014
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hideko Inoue, Nobuharu Ohsawa, Satoko Shitagaki, Satoshi Seo
  • Patent number: 8664384
    Abstract: The use of N6-(ferrocenmethyl)quinazoline-2,4,6-triamine (H2), its derivatives, and prodrugs that present antimicrobial (antibiotic, microbicide), antiparasitic (parasiticide), antiprotozoal (protozoacide), and antileishmanial (leishmanicide) activities, as well as its use as a drug in vertebrates (humans and animals).
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: March 4, 2014
    Assignee: Norma del Carmen Galindo Sevilla
    Inventors: Norma del Carmen Galindo Sevilla, Francisco Hernández Luis
  • Patent number: 8664385
    Abstract: A family of three 8-alkyl boron dipyrromethenes 1, 2, and 3 has been prepared. These compounds are characterized by emission in the green region of the electromagnetic radiation spectrum and exhibit an almost double laser efficiency than other commercial dyes and much greater photostability. The 8-alkyl boron dipyrromethenes are prepared by catalytic hydrogenation (reduction) of the corresponding 8-alkenyl boron dipyrromethenes, which are obtained by Liebeskind-Srogl coupling of thiomethylboron dipyrromethene with an alkenyl boronic acid.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: March 4, 2014
    Assignee: Universidad de Guanajuato
    Inventors: Eduardo Peña Cabrera, Ismael Javier Arroyo Cordova, Fabiola Irene Lopez Vallejo
  • Patent number: 8664386
    Abstract: Methods for isolating 9-{(R)-2-[((S)-{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine (compound 16): a method for preparing, in high diastereomeric purity, intermediate compounds 13 and 15: and a method for preparing intermediate compound 12: 9-{(R)-2-[((S)-{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine has anti-viral properties.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: March 4, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Denise A. Colby, Andrew Anthony Martins, Benjamin James Roberts, Robert William Scott, Nicole S. White
  • Patent number: 8664387
    Abstract: The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: March 4, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Ronald K. Chang, Thomas J. Greshock
  • Patent number: 8664388
    Abstract: The present invention relates to substituted amino-quinazolinones of general formula (I) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: March 4, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Fuchs, Niklas Heine, Christian Eickmeier, Sandra Handschuh, Cornelia Dorner-Ciossek, Stefan Hoerer
  • Patent number: 8664389
    Abstract: The present invention relates to an improved and novel process for the preparation of high purity crystalline base of Lapatinib of formula-(1) having chemical name N-{3-chloro-4-[(3-fluorobenzyloxy]phenyl}-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl]-2-furyl]-4-quin-azolinamine and its pharmaceutically acceptable salts. The present invention further relates to intermediates according to formula (8) and formula (9) used in this process.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: March 4, 2014
    Assignee: Natco Pharma Limited
    Inventors: Ramanadham Jyothi Prasad, Bhujanga Rao Adibhatla Kali Satya, Nannapaneni Venkaiah Chowdary
  • Patent number: 8664390
    Abstract: The present invention relates to an improved process for the preparation of bosentan. In particular it relates to a process for preparing bosentan substantially free from the dimer impurity of formula (II) and the 6-hydroxy impurity of formula (III). The invention also relates to a pharmaceutical composition comprising bosentan and its use in the treatment of endothelin-receptor mediated disorders.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: March 4, 2014
    Assignee: Generics (UK) Limited
    Inventors: Abhay Gaitonde, Bindu Manojkumar, Sandeep Sonawane, Dattatrey Kokane, Sandeep Mekde, Dattatraya Shinde, Prakash Bansode